Feedback / Questions
KIN-102 - Kinimmune
https://www.businesswire.com/news/home/20221109005174/en/Kinimmune-wins-highly-competitive-NCI-funding-to-advance-solid-tumor-immunotherapy-for-patients-refractory-to-checkpoint-inhibitors
Nov 9, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious